Status:
COMPLETED
Tivozanib for Recurrent Glioblastoma
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Comprehensive Cancer Network
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" m...
Detailed Description
If you are willing to participate in this study, you will be asked to undergo some screening tests and procedures that confirm you are eligible. Many of these tests and procedures are likely to be par...
Eligibility Criteria
Inclusion
- Histologically confirmed glioblastoma that has progressed based on imaging or surgery
- Measurable disease
- No more than 3 prior chemotherapy regimens
- Must have recovered from toxicity of prior therapy. An interval of at least 3 months must have elapsed since the completion of the most recent course of radiotherapy; at least 3 weeks since last non-nitrosourea containing chemotherapy regimen or molecularly targeted agent; at least 6 weeks since the completion of a nitrosourea containing chemotherapy regimen
- Life expectancy of at least 12 weeks
- Able to tolerate MRIs
- Willing to use adequate, highly effective contraception measures while on study and for at least 45 days after the last dose of study drug
Exclusion
- Pregnant or breastfeeding
- Major surgical procedure or significant traumatic injury within 28 days of starting therapy; or minor surgical procedure within 7 days
- Receiving other study agents
- Prior therapy with an anti-VEGF agent
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib
- Receiving any medications or substances that are inhibitors or inducers of CYP450 enzymes
- Significant cardiovascular disease
- Non-healing wound, bone fracture or skin ulcer
- Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other gastrointestinal condition with increased risk of perforation; abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug
- Uncontrolled intercurrent illness
- Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug
- Significant bleeding disorders within 6 months prior to administration of first dose of study drug
- Currently active second primary malignancy
- HIV positive and on combination antiretroviral therapy
- Inability to swallow capsules, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of study drugs, major resection of the stomach or small bowel, or gastric bypass procedure
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01846871
Start Date
June 1 2013
End Date
May 1 2016
Last Update
January 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114